https://www.espn.com/mma/story/_/id/35156934/ontario-bans-ufc-betting-integrity-concerns
Agilent Reports Received FDA Companion Diagnostic Approval For Ki-67 pharmDX In High-Risk Early Breast Cancer
Agilent Technologies Inc. (NYSE:A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for